Oncology Med, Inc., a public company engaged in the fulfillment of services related to the treatment of various cancers, announced the execution of a second contract for its new Brachytherapy programs with an ambulatory surgical center located in the Northeastern U.S.. Brachytherapy is the treatment of prostate cancer through the implantation of radioactive seeds. The contract will add $300,000.00 in revenues over the next year, increasing the Company’s run rate by 15% over 12 months.
“I’m extremely pleased with the execution of our second contract for our new prostate cancer brachytherapy program,” said Dr. William J. Walker, Chairman of Oncology Med, Inc. “As we mentioned in our press release dated February 12, 2008, the new rules and changes made to reimbursement policies for ambulatory surgical centers by the Center for Medicare and Medicaid Services will increase the demand for our services to these medical facilities. This second contract is an additional endorsement of the tremendous opportunity available to us and I believe there will be several additional contracts we may enter into in the near future.”
Oncology Med currently provides analysis and design of radiation treatment plans that assist radiation oncologists in administering radiation therapy to cancer patients. The current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
Let us hear your thoughts below: